MedPath

Plitidepsin

Generic Name
Plitidepsin
Drug Type
Small Molecule
Chemical Formula
C57H87N7O15
CAS Number
137219-37-5
Unique Ingredient Identifier
Y76ID234HW
Background

Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.

Indication

Intended for the treatment of various forms of cancer.

Sylentis Reports Positive Phase IIa Results for SYL1801 Eye Drops in Age-Related Macular Degeneration

• Sylentis announced that SYL1801, an investigational siRNA therapy administered as eye drops, met its primary endpoint in a Phase IIa study for neovascular age-related macular degeneration (nAMD). • Over 71% of patients receiving the mid-dose level maintained visual acuity throughout the 6-week study period, with this dose achieving statistically significant improvement in visual acuity at day 42. • SYL1801 represents a potential paradigm shift in AMD treatment, as it could replace uncomfortable intravitreal injections with a more patient-friendly eye drop formulation based on RNA interference technology.

EMA Recommends Approval for New Cancer Treatments and Vaccines

• The European Medicines Agency (EMA) has recommended eight new products for EU-wide approval, expanding treatment options for various conditions. • Several cancer treatments have received positive recommendations, potentially offering new hope for patients with different types of malignancies. • A new antiparasitic combination has been endorsed for use in non-EU markets, addressing a critical need in regions affected by parasitic infections. • The EMA is also reviewing new safety information regarding Leqembi, an Alzheimer's disease treatment, ensuring ongoing monitoring of its benefit-risk profile.
© Copyright 2025. All Rights Reserved by MedPath